Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.
Abstract
Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.
참고문헌 (17)
- Ribas A, "Tumor immunotherapy directed at PD-1", N Engl J Med, 366, pp.2517~2519 (2012)
- Dobosz P, "The intriguing history of cancer immunotherapy", Front Immunol, 10, pp.2965~ (2019)
- Mellman I, "Cancer immunotherapy comes of age", Nature, 480, pp.480~489 (2011)
- Michot JM, "Immune-related adverse events with immune checkpoint blockade : a comprehensive review", Eur J Cancer, 54, pp.139~148 (2016)
- Calvo R, "Hematological side effects of immune checkpoint inhibitors : the example of immune-related thrombocytopenia", Front Pharmacol, 10, pp.454~ (2019)
- Weber JS, "Safety profile of nivolumab monotherapy : a pooled analysis of patients with advanced melanoma", J Clin Oncol, 35, pp.785~792 (2017)
- Gandhi L, "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer", N Engl J Med, 378, pp.2078~2092 (2018)
- Delanoy N, "Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy : a descriptive observational study", Lancet Haematol, 6, pp.e48~e57 (2019)
- Tanios GE, "Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer : 68 cases from the Food and Drug Administration database and review", Eur J Haematol, 102, pp.157~162 (2019)
- Kong BY, "Autoimmune hemolytic anemia induced by anti-PD-1therapy in metastatic melanoma", Melanoma Res, 26, pp.202~204 (2016)
- Packman CH, "The clinical pictures of autoimmune hemolytic anemia", Transfus Med Hemother, 42, pp.317~324 (2015)
- Atiq O, "Pembrolizumab-induced cold agglutinin disease", Am J Case Rep, 21, pp.e924283~ (2020)
- Juwhan Choi, "Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors", Immune Network, 20(1), pp.1~21 (2020), 대한면역학회[DOI]
- Haanen JB, "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28(Suppl 4), pp.IV119~IV142 (2017)
- Mahoney KM, "The next immune-checkpoint inhibitors : PD-1", PD-L1 blockade in melanoma, 2015, pp.37, 764~782
- Nair R, "Immunotherapy-associated hemo lytic anemia with pure red-cell aplasia", N Engl J Med, 374, pp.1096~1097 (2016)
- Palla AR, "Autoimmune hemolytic anemia as a complication of nivolumab therapy", Case Rep Oncol, 9, pp.691~697 (2016)